News for Healthier Living

Immunotherapy Improves Survival of Patients with Locally Advanced Head and Neck Cancer

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

April 27, 2025


April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025

April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025

April 15 2025